バンコマイシン耐性ブドウ球菌感染症は、細菌によって引き起こされる疾患です。この感染症は、黄色ブドウ球菌またはStaphと呼ばれる細菌が、抗生物質バンコマイシンに耐性を持つ（死滅しない）ようになった場合に起こります。危険因子としては、強い抗生物質を間違った方法で服用すると細菌が抗生物質に対して耐性を獲得する可能性があること、免疫システムが弱いこと、病院に長く入院していることなどが挙げられます。症状としては、発熱、悪寒、咳、胸痛、呼吸困難、心拍の速さなどがあります。
目次
Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Overview
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Companies Involved in Therapeutics Development
Amprologix Ltd
CrystalGenomics Inc
Destiny Pharma Plc
Lysimmune BioScience
Sano Chemicals Inc
TAXIS Pharmaceuticals Inc
TGV-Inhalonix Inc
Therapeutic Systems Research Laboratories Inc
Wockhardt Ltd
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drug Profiles
APY-281 - Drug Profile
Product Description
Mechanism Of Action
CG-549 - Drug Profile
Product Description
Mechanism Of Action
Epidermicin NI-01 - Drug Profile
Product Description
Mechanism Of Action
exeporfinium chloride - Drug Profile
Product Description
Mechanism Of Action
LI-03 - Drug Profile
Product Description
Mechanism Of Action
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
MUT-001 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit crtN for Staphylococcus aureus Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit PBP2 for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit PBP2a for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Gram Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for MRSA and VRSA Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Methionine tRNA Ligase for Gram Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
TXA-709 - Drug Profile
Product Description
Mechanism Of Action
WCK-4086 - Drug Profile
Product Description
Mechanism Of Action
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Amprologix Ltd, 2022
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by CrystalGenomics Inc, 2022
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Destiny Pharma Plc, 2022
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Lysimmune BioScience, 2022
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Sano Chemicals Inc, 2022
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by TAXIS Pharmaceuticals Inc, 2022
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by TGV-Inhalonix Inc, 2022
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Therapeutic Systems Research Laboratories Inc, 2022
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Wockhardt Ltd, 2022
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects, 2022
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products, 2022
List of Figures
Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
